MABVAX THERAPEUTICS
MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. B... oth trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.
MABVAX THERAPEUTICS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
2006-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.mabvax.com
Total Employee:
11+
Status:
Active
Contact:
(858)259-9405
Email Addresses:
[email protected]
Total Funding:
61.45 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail IPv6 ReCAPTCHA Amazon Virginia Region Microsoft Network Solutions DNS Amazon California Region
Similar Organizations
Allonnia
Allonnia is an environmental biotechnology company focused on metals and mining, plastics and PFAS, plus other emerging contaminants.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
COBRE Center for Central Nervous System Function
COBRE is a National Institute for General Medical Sciences program.
Cytos
Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies .
DARA BioSciences
DARA is a pharmaceutical company commercializing treatments and supportive care products for oncology.
Farmax
Farmax is a pharmaceutical company that specializes in the fields of the medical, pharmacy, and healthcare industry.
Genocea Biosciences
Genocea Biosciences is a biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies.
P&PMed
P&PMed is the first biomedical company to focus on the research and application of personalized cancer vaccines.
Lengo Therapeutics
Lengo Therapeutics a biopharmaceutical company focused on the discovery and development of cancer treatments.
Ligand Pharmaceuticals
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies.
Marizyme
Marizyme is a development-stage company dedicated to the commercialization of therapies that address the urgent need of higher mortality.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
RiboNova Inc.
RiboNova is a biopharmaceutical company in the Lankenau Institute for Medical Research. near Philadelphia
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2014-05-12 | Telik | Telik acquired by MabVax Therapeutics | N/A |
Investors List
Boehringer Ingelheim
Boehringer Ingelheim investment in Post-IPO Equity - MabVax Therapeutics
Phillip Frost
Phillip Frost investment in Post-IPO Equity - MabVax Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - MabVax Therapeutics
Burrill & Company
Burrill & Company investment in Series B - MabVax Therapeutics
Numoda Capital Innovations
Numoda Capital Innovations investment in Series B - MabVax Therapeutics
Biomark Capital
Biomark Capital investment in Venture Round - MabVax Therapeutics
GBP Capital
GBP Capital investment in Series A - MabVax Therapeutics
Official Site Inspections
http://www.mabvax.com
- Host name: ec2-54-208-101-55.compute-1.amazonaws.com
- IP address: 54.208.101.55
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "MabVax Therapeutics"
MabVax Therapeutics, Inc. - LinkedIn
MabVax Therapeutics (Nasdaq: MBVX) is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products...See details»
MabVax Therapeutics Company Profile 2024: Valuation, …
MabVax Therapeutics Holdings Inc is a development-stage biopharmaceutical company works to discover, develop, and commercialize small molecule drugs to treat cancer-related illnesses.See details»
Mabvax Therapeutics Holdings Inc (MBVX) Profile - The Globe and …
See the company profile for Mabvax Therapeutics Holdings Inc (MBVX) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
MabVax Therapeutics Holdings Inc - Company Profile and News
MabVax Therapeutics Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, develops human antibody-based products and vaccines to address unmet …See details»
MabVax Therapeutics Holdings, Inc. Provides …
Oct 17, 2017 · MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform …See details»
MabVax Therapeutics Holdings, Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for MabVax Therapeutics Holdings, Inc. of San Diego, CA. Get the latest business insights from Dun & …See details»
MabVax Therapeutics and Oncotelic Enter into Merger Discussions
Jan 4, 2019 · Oncotelic is developing a unique TGF-b antisense therapy which has demonstrated the ability to break immune tolerance in mid-stage clinical trials for the treatment of …See details»
David Hansen - MabVax Therapeutics, Inc. | LinkedIn
Hansen has proven leadership abilities in creating, building, and directing small start-up operations and key departments in both large and small biopharmaceutical companies. He has broad...See details»
MabVax starts dosing patients in Phase l trial of MVT-1075
Dec 15, 2017 · MabVax Therapeutics has started dosing patients in the initial round of a Phase l clinical trial evaluating MVT-1075 for the treatment of pancreatic, colon and lung cancers.See details»
MabVax execs sued by investor who settled stock manipulation …
Jul 29, 2020 · In a complaint filed Tuesday in Manhattan federal court, Florida investor Barry Honig, represented by Michael Sommer of Wilson Sonsini Goodrich & Rosati, accused …See details»
MabVax Therapeutics Holdings, Inc. Provides Business Strategy …
Jan 16, 2018 · MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical …See details»
David Hansen - Hansen Consulting - Independent Management
Formerly CEO and Chairman of MabVax Therapeutics Holdings, Inc. · Senior corporate executive with diverse and in-depth experience in the biopharmaceutical industry including; Executive …See details»
Mabvax Therapeutics Holdings Inc (MBVX) Stock Price and News
MabVax Therapeutics Holdings, Inc. is a clinical-stage drug development company. It is focused on discovering and developing small molecule drugs to treat cancer.See details»
MabVax Brass Slip Suit By Alleged Pump-And-Dump Investor
Oct 7, 2021 · "A New York federal judge has dismissed claims by an alleged pump-and-dump scheme mastermind that former top executives at biotech company MabVax Therapeutics hid …See details»
BioNTech's mRNA Technology and Acquired Oncology Programs …
Mar 20, 2024 · BioNTech acquired MabVax's assets and labs in May 2019, adding BNT321, a targeted antibody in phase 1 for pancreatic cancer, which is extremely aggressive and deadly, …See details»
MabVax Therapeutics and Boehringer Ingelheim Sign Asset …
Jul 9, 2018 · MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical …See details»
MabVax Wins $1.8M SBIR Grant to Support Phase II Sarcoma …
Apr 11, 2011 · MabVax Therapeutics has received a $1.8 million Phase 2 SBIR grant from the NCI to support a Phase II trial evaluating its trivalent sarcoma vaccine. The new award follows …See details»
MabVax Therapeutics Blames Bankruptcy on Alleged Pump-and …
Mar 21, 2019 · MabVax Therapeutics Holdings Inc., a developer of cancer treatments, filed for bankruptcy protection Thursday, saying the business deteriorated when regulators charged …See details»
Meeting Abstract: 2018 ASCO Annual Meeting I - ASCO Publications
HuMab-5B1 (MVT-5873), a mAb targeting sLe a, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 …See details»
Retooling a Blood-Based Biomarker: Phase I Assessment of the …
Dec 2, 2019 · The fully human HuMab-5B1 antibody was manufactured for MabVax Therapeutics Holdings, Inc. by Patheon Biologics under current good manufacturing practice guidelines and …See details»